Endocrine Abstracts

Objective: The exogenous somatostatin inhibits insulin secretion in pancreatic cell and could lead to hyperglycemia. But, Glucagon-like peptide-1 (GLP-1) has insulinotropic actions despite stimulating somatostatin secretion in δ cell. So, we examined whether there is a time difference of insulin and somatostatin secretion after GLP-1 stimulation or secretion rate difference of insulin and somatostatin depending on GLP-1 concentration and glucose concentration ins...

Background: The National Health Insurance Service of South Korea is considered to be one of the most effective systems in the world with high accessibility to health care for all Koreans including foreign residents in the country as many as 50 M people. The accumulative information on the behaviors and the statistics of healthcare use based on the National Health Insurance Sharing Service Database has become important for medical research as a nationwide surveillance.<p cl...

Glucagon-like peptide-1 (GLP-1) is known to stimulate insulin and somatostatin secretion in pancreatic islet cells. The exogenous somatostatin inhibits insulin secretion, but GLP-1 increases insulin secretion in spite of stimulating somatostatin secretion from δ-cell. So, we investigated whether there exists a time difference of insulin and somatostatin secretion inside the islets after GLP-1 stimulation or insulin secretion depends on secreted GLP-1 or somatostatin conce...

Background: PD-1/PD-L1 blockade is one of the promising drugs in the treatment of advanced non-small cell lung cancer (NSCLC). and predicting drug effect is important due to unique pattern of response. Immune-related adverse event (IRAE) might be associated with favorable clinical outcome. Thyroiditis is the most common IRAE which can be easily detected with the measurement of thyroid hormone levels. However, the relationship between thyroid dysfunction during the use of PD-1/...